Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
$9.15
+3.6%
$8.66
$6.82
$23.29
$1.41B0.883.25 million shs486,171 shs
Defiance Daily Target 2X Long LMND ETF stock logo
LMNX
Defiance Daily Target 2X Long LMND ETF
$12.57
+2.4%
$14.29
$10.17
$55.00
$4.15M-7.6442,795 shs11,207 shs
Pulmonx Corporation stock logo
LUNG
Pulmonx
$1.30
+3.6%
$1.39
$1.13
$3.88
$54.70M0.28461,946 shs124,707 shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
+1.49%+0.23%+9.55%-19.21%-21.44%
Defiance Daily Target 2X Long LMND ETF stock logo
LMNX
Defiance Daily Target 2X Long LMND ETF
-4.06%-10.69%-9.84%-40.38%-66.80%
Pulmonx Corporation stock logo
LUNG
Pulmonx
-10.07%-1.96%-20.38%+6.84%-52.47%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
$9.15
+3.6%
$8.66
$6.82
$23.29
$1.41B0.883.25 million shs486,171 shs
Defiance Daily Target 2X Long LMND ETF stock logo
LMNX
Defiance Daily Target 2X Long LMND ETF
$12.57
+2.4%
$14.29
$10.17
$55.00
$4.15M-7.6442,795 shs11,207 shs
Pulmonx Corporation stock logo
LUNG
Pulmonx
$1.30
+3.6%
$1.39
$1.13
$3.88
$54.70M0.28461,946 shs124,707 shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
+1.49%+0.23%+9.55%-19.21%-21.44%
Defiance Daily Target 2X Long LMND ETF stock logo
LMNX
Defiance Daily Target 2X Long LMND ETF
-4.06%-10.69%-9.84%-40.38%-66.80%
Pulmonx Corporation stock logo
LUNG
Pulmonx
-10.07%-1.96%-20.38%+6.84%-52.47%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
2.75
Moderate Buy$18.58105.45% Upside
Defiance Daily Target 2X Long LMND ETF stock logo
LMNX
Defiance Daily Target 2X Long LMND ETF
0.00
N/AN/AN/A
Pulmonx Corporation stock logo
LUNG
Pulmonx
2.43
Hold$5.58334.50% Upside

Current Analyst Ratings Breakdown

Latest ATEC, LUNG, and LMNX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2026
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
Lower Price TargetOverweight$27.00 ➝ $24.00
5/7/2026
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
Lower Price TargetOverweight$28.00 ➝ $14.00
5/7/2026
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
Reiterated RatingBuy$24.00
5/6/2026
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
UpgradeSell (E+)Sell (D-)
5/6/2026
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
Reiterated RatingBuy$15.00
5/6/2026
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
Lower Price TargetBuy$25.00 ➝ $23.00
5/6/2026
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
Reiterated RatingOverweight$25.00 ➝ $14.00
5/6/2026
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
Set Price TargetOverweight$27.00 ➝ $24.00
5/6/2026
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
Lower Price TargetOverweight$24.00 ➝ $16.00
5/6/2026
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
Lower Price TargetBuy$20.00 ➝ $11.00
4/30/2026
Pulmonx Corporation stock logo
LUNG
Pulmonx
Reiterated RatingBuy$14.00
(Data available from 6/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
$764.16M1.82N/AN/A$0.08 per share113.06
Defiance Daily Target 2X Long LMND ETF stock logo
LMNX
Defiance Daily Target 2X Long LMND ETF
$437.66M0.01$0.37 per share32.98$11.13 per share1.11
Pulmonx Corporation stock logo
LUNG
Pulmonx
$90.50M0.60N/AN/A$1.31 per share0.98
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
-$143.36M-$0.82N/A180.90N/A-15.93%-1,183.84%-15.83%7/30/2026 (Estimated)
Defiance Daily Target 2X Long LMND ETF stock logo
LMNX
Defiance Daily Target 2X Long LMND ETF
$15.17M$0.5124.1210.25N/A5.39%4.66%2.91%N/A
Pulmonx Corporation stock logo
LUNG
Pulmonx
-$54M-$1.30N/AN/AN/A-60.09%-92.94%-39.80%7/29/2026 (Estimated)

Latest ATEC, LUNG, and LMNX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/29/2026Q1 2026
Pulmonx Corporation stock logo
LUNG
Pulmonx
-$0.33-$0.33N/A-$0.33$20.43 million$20.59 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
N/AN/AN/AN/AN/A
Defiance Daily Target 2X Long LMND ETF stock logo
LMNX
Defiance Daily Target 2X Long LMND ETF
$0.403.25%N/A78.43%N/A
Pulmonx Corporation stock logo
LUNG
Pulmonx
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
40.35
1.90
1.12
Defiance Daily Target 2X Long LMND ETF stock logo
LMNX
Defiance Daily Target 2X Long LMND ETF
0.52
8.37
6.08
Pulmonx Corporation stock logo
LUNG
Pulmonx
0.81
4.91
4.04

Institutional Ownership

CompanyInstitutional Ownership
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
66.35%
Defiance Daily Target 2X Long LMND ETF stock logo
LMNX
Defiance Daily Target 2X Long LMND ETF
87.76%
Pulmonx Corporation stock logo
LUNG
Pulmonx
91.04%

Insider Ownership

CompanyInsider Ownership
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
13.48%
Defiance Daily Target 2X Long LMND ETF stock logo
LMNX
Defiance Daily Target 2X Long LMND ETF
6.60%
Pulmonx Corporation stock logo
LUNG
Pulmonx
6.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
700153.79 million133.06 millionOptionable
Defiance Daily Target 2X Long LMND ETF stock logo
LMNX
Defiance Daily Target 2X Long LMND ETF
1,325330,000N/AOptionable
Pulmonx Corporation stock logo
LUNG
Pulmonx
25042.24 million39.37 millionOptionable

Recent News About These Companies

Pulmonx Reports First Quarter 2026 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alphatec stock logo

Alphatec NASDAQ:ATEC

$9.14 +0.32 (+3.57%)
As of 12:11 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

Defiance Daily Target 2X Long LMND ETF stock logo

Defiance Daily Target 2X Long LMND ETF NASDAQ:LMNX

$12.57 +0.29 (+2.36%)
As of 11:28 AM Eastern

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. Luminex Corporation was founded in 1995 and is based in Austin, Texas.

Pulmonx stock logo

Pulmonx NASDAQ:LUNG

$1.30 +0.05 (+3.60%)
As of 12:10 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.